Skip to main content

Table 1 The fourfold table of disproportionality measurement

From: Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System

Drug

Number of Reports of Target AEs

Number of Reports of Other AEs

Total

Target Drug

a

b

a + b

Other Drugs

c

d

c + d

Total

a + c

b + d

a + b + c + d